Pharming Group N.V. ADR
PHAR
Pharming Group N.V. ADR is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its current portfolio centers on protein replacement therapies and precision medicines, with products designed to address conditions that have limited treatment options. The company’s marketed medicines include RUCONEST, used for acute hereditary angioedema, and Joenja, an oral therapy for APDS, reflecting its emphasis on specialist treatments for underserved patient groups. Pharming Group also operates across clinical development, manufacturing, regulatory affairs, and commercialization, supporting the full lifecycle of its medicines. Based in Leiden, the Netherlands, Pharming Group N.V. ADR plays a role in the rare disease market by combining scientific development with commercial execution in the global healthcare sector.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$366M
▲ +26.6% YoY
Net Income (TTM)
$9M
▲ +121.4% YoY
Op. Margin
3.37%
▲ +6.8pp YoY
ROIC
2.88%
▲ +3.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$34M
▲ +2182.3% YoY
Op. Cash Flow (TTM)
$35M
▲ +471.2% YoY
Net Debt
-$63M
Net Cash Position
Cash & Equiv.
$179M
3Y CAGR: +22.3%
3Y CAGR: +38.1%
Continue Research
Peers
Biotechnology · Pick stocks to compare with PHAR
Pharming Group N.V. ADR (PHAR) in four numbers
Questions about Pharming Group N.V. ADR
Is Pharming Group N.V. ADR (PHAR) overvalued?
At $11.54, Pharming Group N.V. ADR's price is 398% above the $2.32 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 92.68 times earnings and 25.01 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Pharming Group N.V. ADR's fair value?
Intrinsiqq's calculator puts Pharming Group N.V. ADR's fair value at $2.32 a share. It grows earnings per share 0% a year for 5 years, applies an exit P/E of 30, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $1.74. Every input can be changed on the Intrinsic Value tab.
Is Pharming Group N.V. ADR a high-quality business?
Pharming Group N.V. ADR scores 56 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 8 checks computed from company filings. Its best check is revenue growth at 15.5%, and its weakest is return on capital at 2.9%. The Quality tab shows every check against its target.
Does Pharming Group N.V. ADR (PHAR) pay a dividend?
No. Pharming Group N.V. ADR (PHAR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PHAR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.